Relationship Between Histomorphological Typing And Immunohistochemistry Expression Of Breast Prognostic Markers (ER, PR, Her2neu) In Breast Carcinoma At A Tertiary Care Hospital
DOI:
https://doi.org/10.52783/jns.v14.2802Keywords:
N/AAbstract
Background: Breast cancer remains the most prevalent cancer in Indian women. The histopathological examination by morphology, accompanied by the recommendation to assess hormone receptors—specifically Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2—by the College of American Pathologists and the American Society of Clinical Oncology, are widely recommended due to their prognostic and therapeutic values. Immunohistochemical characterization and gene examination are also essential, as cumulative results reveal the importance of hormone receptors in breast cancer. This study aims to retrospectively analyze the positivity rate of hormone receptors and HER2 in breast cancer patients.
Materials and Methods: The study, conducted over three years, included 51 cases of breast carcinoma, managed at Sharda Hospital, Sharda University. Samples were tested through immunohistochemistry against ER, PR, and HER2, citing ASCO/CAP Guidelines. The results were correlated with clinicopathological and histopathological data.
Results: ER and PR expression were proportionally greater in younger patients (<50 years), similar to HER2. A significant correlation of ER and PR was observed with increasing tumor grade, with p-values of 0.0115 and 0.0378, respectively. No significant correlation was found for Her2neu with tumor grade, with nodal status, or with age/menopausal status. ER and PR involvement significantly decreases as tumor grade increases.
Downloads
Metrics
References
Cherney kristeen. What to Know About Breast Lesions [Internet]. 2022 [cited 2023 May 9]. Available from: https://www.healthline.com/health/womens-health/lesions-breast#takeaway
6. De Santis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–418.
International Agency for Research on Cancer. India Source: Globocan 2020. [cited 11June2021].Available from: https://gco.iarc.fr/today/data/factsheets/populations/356-indiafact-sheets.pdf
Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. 15 International journal of women's health. 2015 Apr 16:405-14.
Reiner A, Reiner G, Spona J. Histopathologic characterization of human breast cancer in correlation with ER status: A comparision of immunocytochemical and biochemical analysis. Cancer. 1988; 64: 1149-54.
Lesser ML, Rosen PP, Seine RT. Estrogen and progesterone receptors in breast carcinoma; correlations with epidemiology and pathology.Cancer.1981;48: 299- 309.
National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In, Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR): 2006. 8-30.
K. The pectoral region In : Chaurasia BD, editor. Human anatomy. 4th edition, New Delhi. CBS publishers and distributors 2004; 34-44.
Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives [published correction appears in Surg Oncol Clin N Am. 2014 Oct;23(4):xv]. Surg Oncol Clin N Am. 2014;23(3):567-577. doi:10.1016/j.soc.2014.03.003
Clarke RB, Howell A, Potten CS, and Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-4991.
Jonnada PK, Sushma C, Karyampudi M, Dharanikota A. Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis. Indian J Surg Oncol. 2021;12(Suppl 1):152-163. doi:10.1007/s13193-020-01253-w
Thiygarajan M, Navrathan N, Mohanapriya T, Kumar A, Singh B. Correlation between estrogen receptor, progesterone receptor, HER-2/neu status and other prognostic factors in carcinoma breast in Indian population. Int Surg J. 2015;2(4)515-22.
Kaur K, Kaur H, Gill HS, Kaur M. Evaluation of expression and correlation of ER, PR and Ki67 tumour markers in breast carcinoma. Int J Contemp Med Res. 2016;3(10)3047-3051.
Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumours of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer. 2011;48(4)391-396.
Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India- a study of 798 tumours. Breast. 2000;9(5)267-270.
Tewari M, Pradhan S, Singh U, Shukla HS. Estrogen and progesterone receptor status in breast cancer- effect of oral contraceptive pills and hormone replacement therapy. Breast. 2007;16(5)540-545.
Rashmi K, Sharma J, Minhas SS, Mardi K. Hormone Receptor Status of Breast Cancer in the Himalayan Region of Northern India. Indian J Surg. 2011;73(1)9-12.
Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, Faridi N. Ki67 index in breast cancer- correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013;14(7)4353-4358.
Juneja S, Agarwal R, Agarwal D, Rana P, Singh K, Kaur S. Correlation of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 with histopathological grade in cases of carcinoma breast. Int J Contemp Med Res. 2019;6(9)I6-I11.
Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her2 neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. E cancer medical science. 2012;6;283.
Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbas F. Significance of Her2 neu oncoprotein over expression on node positive invasive breast cancer. J Coll Physicians Surg Pak. 2002;12;534-537.
Soliman NA, Yussif SM. Ki 67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4)496-504.
Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5)747-754.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer- prognostic and predictive potential. Lancet Oncol. 2010;11(2)174-183.
Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996;2(3)585-592.
Fatima S, Faridi N, Gill S. Breast cancer- steroid receptors and other prognostic indicators. J Coll Physicians Surg Pak. 2005;15(4)230-233.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
